Table 1b.
Antidepressants in Treatment of Depressive Symptoms
| Antidepressant Group | Author(s) | Year | Antidepressant |
Dose,
mg |
Antipsychotic | N |
Duration,
wk |
Efficacy
Measures |
Outcome |
|---|---|---|---|---|---|---|---|---|---|
| TCA | Siris et al. | 2000 | Imipramine | n/r | Flufenazine decanoate | 70 | 6 | HDRS, SADS | Improvement in imipramine group. |
| SSRIs | Spina et al. | 1994 | Fluoxetine | 20 | Various FGAs | 34 | 12 | HDRS | Improvement in fluoxetine group. |
| Buchanan et al. | 1996 | Fluoxetine | 20 | Clozapine | 33 | 8 | n/r | No change in either group. | |
| Arango et al. | 2000 | Fluoxetine | 20–40 | Various FGAs | 32 | 8 | HDRS | No change in either group. | |
| Bustillo et al.* | 2003 | Fluoxetine | 60 | Olanzapine | 31 | 8 | HDRS | No change in either group. | |
| Mulholand et al. | 2003 | Sertraline | 50 | Various FGAs, risperidone | 26 | 8 | HDRS, BDI | Improvement on both measures in sertraline group. | |
| Jockers et al. | 2005 | Paroxetine | 30 | Various FGAs and SGAs | 29 | 12 | HDRS | No change in either group. | |
| Iancu et al. | 2010 | Escitalopram | 20 | Various FGAs and SGAs | 38 | 10 | HDRS | No change in either group. | |
| NRI | Schutz and Berk | 2001 | Reboxetine | 8 | Haloperidol | 30 | 8 | HDRS | No change in either group. |
| Poyurovski et al.* | 2003 | Reboxetine | 4 | Olanzapine | 26 | 6 | HDRS | Improvement in reboxetine group. | |
| SNRI | Mico et al. | 2011 | Duloxetine | 60 | Clozapine | 33 | 16 | CDSS | Improvement in duloxetine group. |
| NDRI | Dufresne et al. | 1988 | Bupropion | 300 | FGAs | 38 | 12 | BPRS | Reduction of depressive symptoms in placebo group. |
| Evins et al.* | 2005 | Bupropion | 300 | Clozapine, FGAs, SGAs | 53 | 12 | HDRS | No change in either group. | |
| Receptor-blocking antidepressants | Shiloh et al. | 2002 | Mianserin | 30 | Haloperidol, perphenazine | 18 | 6 | HDRS | Improvement on the HDRS in both groups with no between-group difference. |
| Poyurovski et al. | 2003 | Mianserin | 15 | Various FGAs | 30 | 4 | HDRS | No change in either group. | |
| Stryjer et al.* | 2010 | Trazodone | 100 | n/r | 13 | 1 | HDRS | No change in either group. | |
| Zoccali et al. | 2004 | Mirtazapine | 30 | Clozapine | 24 | 8 | BPRS (depressive factor) | No change in either group. | |
| Berk et al. | 2009 | Mirtazapine | 30 | Various SGAs | 40 | 6 | CDSS, HDRS | No change in either group. | |
| Terevnikov et al. | 2011 | Mirtazapine | 30 | Various FGAs | 41 | 6 | CDSS, PANSS (depression item) | Improvement on both measures in mirtazapine group. |